Covid19 Clinical Trial
Official title:
A Phase III Confirmatory Study of K-237-Multi-regional, Multi-center, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Mild COVID-19
Verified date | August 2022 |
Source | Kowa Company, Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The efficacy and safety of K-237 0.3-0.4 mg/kg orally administered once daily for 3 days will be evaluated in patients with mild COVID-19 using a randomized, double-blind, parallel-group comparative method with placebo as a control. Efficacy will be assessed using a stratified log-rank test to determine the superiority of the drug over placebo in terms of time to improvement in clinical symptoms from the start of study drug administration to 168 hours.
Status | Active, not recruiting |
Enrollment | 1030 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: Persons who meet all of the following criteria will be eligible for this clinical trial. 1. Males and females who are 12 years of age or older at the time of obtaining consent 2. Those who are confirmed positive for SARS-CoV-2 by antigen test or RT-PCR test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 120 hours prior to obtaining consent. 3. Patients who have fevers (37.5 degrees Celsius or higher) and/or at least one of the following symptoms of Score 2 or higher at a screening test: Myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath. 4. Patients with a room air oxygen saturation (SpO2) of 96% or higher at the time of the screening test. Exclusion Criteria: - Subjects who meet any one of the following criteria will be excluded from this study. 1. Patients who have had symptoms caused by COVID-19 for more than 6 days on the day of initiation of study drug administration (Day 1) with the day of onset of symptoms as Day 0. 2. Patients who need to receive concomitant therapy or administration of prohibited drugs during the study period 3. Patients who have taken or received drugs that have or may have antiviral activity against SARS-CoV-2 within 2 weeks prior to the start of study drug administration. 4. Patients currently using antiviral drugs 5. Patients with suspected complications of infectious diseases other than COVID-19 6. Subjects with a history of COVID-19 within 1 month prior to obtaining consent 7. Persons whose weight at the time of the screening test falls into the following categories (The first decimal place of the weight shall be rounded off.) 1) Those who are 18 years of age or older at the time of consent and weigh less than 25 kg or more than 127 kg 2) Those who are between 12 and 18 years of age and weigh less than 40 kg or 127 kg or more at the time of obtaining consent. 8. Patients undergoing dialysis treatment 9. Patients wno have severe liver dysfunction (hepatic dysfunction, hepatic fibrosis, etc.) 10. Patients with poorly controlled hypertension (systolic blood pressure (SBP) of 180 mmHg or higher or diastolic blood pressure (DBP) of 110 mmHg or higher) 11. Patients with complications of diabetic retinopathy, diabetic nephropathy, or diabetic neuropathy 12. Patients with heart failure of NYHA Class III or higher 13. Patients with malignant tumors or those judged to have a high possibility of recurrence 14. Patients requiring oxygen therapy 15. A person who has a complication of methemoglobinemia or any other disease that may cause measurement error of the pulse oximeter 16. Patients with a history of serious drug allergy (anaphylactic shock, etc.) 17. Pregnant women, lactating women, or women who plan to become pregnant or lactate during the study period 18. Subjects who have had more than 400 mL of whole blood drawn within 16 weeks or more than 200 mL within 4 weeks prior to obtaining consent, or component blood (plasma and platelet components) drawn within 2 weeks 19. Patients who have been administered IVM. 20. Those who have participated in other clinical trials and received medication at the time of obtaining consent, or those who have received an investigational drug other than placebo for less than 16 weeks 21. Others who are judged by the investigator or others to be inappropriate to participate in the study. |
Country | Name | City | State |
---|---|---|---|
Japan | Hosokawa Surgical Clinic | Aichi | |
Japan | Nagoya City University East Medical Center | Aichi | |
Japan | Nagoya City University Hospital | Aichi | |
Japan | Nagoya City University West Medical Center | Aichi | |
Japan | Naika Tonyobyonaika Maejima Iin | Aichi | |
Japan | Tohno Chuo Clinic | Aichi | |
Japan | International University of Health and Welfare Narita Hospital | Chiba | |
Japan | Japan Community Health care Organization Funabashi Central Hospital | Chiba | |
Japan | Kamagaya General Hospital | Chiba | |
Japan | Fukuoka Kinen Hospital | Fukuoka | |
Japan | National Hospital Organization Fukuokahigashi Medical Center | Fukuoka | |
Japan | National Hospital Organization Takasaki General Medical Center | Gunma | |
Japan | Hiroshima Prefectural Hospital | Hiroshima | |
Japan | Japan Community Health care Organization Hokkaido Hospital | Hokkaido | |
Japan | National Hospital Organization Kanazawa Medical Center | Ishikawa | |
Japan | Sakaide City Hospital | Kagawa | |
Japan | Tenyoukai Central Hospital | Kagoshima | |
Japan | Kawasaki Rinko General Hospital | Kanagawa | |
Japan | Kitasato University Hospital | Kanagawa | |
Japan | Maekawa Medical Clinic | Kanagawa | |
Japan | Matsuba Clinic | Kanagawa | |
Japan | Mutsukawa Clinic Primary care and Gastroenterology | Kanagawa | |
Japan | Tsuzuki Azuma Clinic Primary care and Rheumatology | Kanagawa | |
Japan | NHO Kumamoto Saishun Medical Center | Kumamoto | |
Japan | Sakura Jyuji Hospital, Sakurajyuji Medical Corporation | Kumamoto | |
Japan | Minami Nagano Clinic | Nagano | |
Japan | Japan Organization of Occupational Health and Safety Nagasaki Rosai Hospital | Nagasaki | |
Japan | Ikoma City Hospital | Nara | |
Japan | Nagaoka Chuo General Hospital | Niigata | |
Japan | Okayama City General Medical Center Okayama City Hospital | Okayama | |
Japan | Okayama University Hospital | Okayama | |
Japan | Japan Community Health care Organization Osaka Minato Central Hospital | Osaka | |
Japan | Rinku General Medical Center | Osaka | |
Japan | Tazuke Kofukai Medical Research Institute, Kitano Hospital | Osaka | |
Japan | Omi Medical Center | Shiga | |
Japan | Kuramochi Clinic Interpark | Tochigi | |
Japan | Edogawa Hospital | Tokyo | |
Japan | Kitasato University Kitasato Institute Hospital | Tokyo | |
Japan | Koto Hospital | Tokyo | |
Japan | Minamino Cardiovascular Hospital | Tokyo | |
Japan | Mishuku Hospital | Tokyo | |
Japan | Ome Municipal General Hospital | Tokyo | |
Japan | Shimamura Memorial Hospital | Tokyo | |
Japan | Sumida General Clinic | Tokyo | |
Japan | Tokyo center clinic | Tokyo | |
Japan | Tokyo Medical University Hachioji Medical Center | Tokyo | |
Japan | Tokyo Saiseikai Central Hospital | Tokyo | |
Japan | Japan Organization of Occupational Health and Safety Toyama Rosai Hospital | Toyama | |
Japan | Toyama City Hospital | Toyama | |
Japan | Toyama University Hospital | Toyama | |
Japan | Japan Organization of Occupational Health and Safety Wakayama Rosai Hospital | Wakayama | |
Japan | National Hospital Organization Minami Wakayama Medical Center | Wakayama | |
Thailand | Srinagarind Hospital | Khon Kaen | |
Thailand | Bamrasnaradura Infectious Diseases Institute | Nonthaburi | |
Thailand | Ratchaburi Hospital | Ratchaburi Provinc |
Lead Sponsor | Collaborator |
---|---|
Kowa Company, Ltd. |
Japan, Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time from the start of study drug administration to 168 hours until the clinical symptoms reach an improving trend | Day1~11 after administration | ||
Secondary | In addition to the primary endpoint, time to trend toward improvement in clinical symptoms, including headache, abdominal pain, nasal | Day1~11 after administration | ||
Secondary | Time to reach a temperature of less than 37.5 °C without the use of antipyretics (acetaminophen) | Day1~11 after administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |